|
|
|
|
 |
Press Releases
All Releases
 |
Pain Therapeutics Reports Q1 2012 Financial Results
May 8, 2012
|
16.8 KB |
|
| |
AUSTIN, Texas, May 8, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter ended March 31, 2012. Net profit for Q1 2012 was $30,000, or $0.00 per share in Q1 2012, as compared to a net loss of $207,000, or $0.00 per share in Q1 2011.
Cash and investments were $95.9 million at March 31,...
|
 |
Four U.S. Patents Issued for REMOXY
May 3, 2012
|
9.4 KB |
|
| |
AUSTIN, Texas, May 3, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics Inc. (Nasdaq:PTIE) a biopharmaceutical company, today announced the issuance of four patents by the U.S. Patent and Trademark Office covering REMOXY® (oxycodone) Extended-Release Capsules CII. These patents are the result of joint inventive work by scientists from both Pain Thera...
|
 |
Pain Therapeutics Reports 2011 Financial Results
Feb 9, 2012
|
18.5 KB |
|
| |
— Balance Sheet Remains Strong —— Disciplined Spending Expected in 2012 —
AUSTIN, Texas, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the full year ended December 31, 2011. Net loss was $2.6 million in 2011, or $0.06 per share, compared to a net loss of $12.0...
|
 |
Pain Therapeutics Reports Q3 2011 Financial Results
Nov 3, 2011
|
18.4 KB |
|
| |
Cash Position Remains Strong at Almost $100 MillionExpenses Remain Well-Controlled
AUSTIN, Texas, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the third quarter of 2011, which ended September 30, 2011. Net loss was $0.8 million, or $0.02 per share. We ended the quarter with cash and...
|
 |
Pain Therapeutics Reports Q2 2011 Financial Results
Aug 4, 2011
|
18.3 KB |
|
| |
AUSTIN, Texas, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for its second quarter, which ended June 30, 2011. Net loss was $1.2 million, or $0.03 per share. We ended the quarter with cash and investments of $101.0 million. We still expect net cash requirements in 2011 to be under $5.0 mill...
|
 |
FDA Complete Response Letter Received for REMOXY
Jun 27, 2011
|
10.4 KB |
|
| |
AUSTIN, Texas, June 27, 2011 (GLOBE NEWSWIRE) -- As previously announced by Pain Therapeutics Inc. (Nasdaq:PTIE), a Complete Response Letter was received on June 23, 2011 from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII.
Based on its...
|
| |
FDA Complete Response Letter Received for REMOXY
Jun 24, 2011
|
131.3 KB |
|
 |
Pain Therapeutics to Present at Jefferies Healthcare Conference
Jun 2, 2011
|
8.2 KB |
|
| |
AUSTIN, Texas, June 2, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at Jefferies 2011 Global Healthcare Conference in New York City on Thursday, June 9th at 10:00 a.m. Eastern Time.
A live audio webcast of the presentation will be available on the company's website homepage at www.p...
|
 |
Pain Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference
May 5, 2011
|
8.2 KB |
|
| |
AUSTIN, May 5, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at the 2011 Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada on Wednesday, May 11th at 3:40 p.m. Pacific Time.
A live audio webcast of the presentation will be available on the company's website h...
|
 |
Pain Therapeutics Reports Q1 2011 Financial Results
Apr 27, 2011
|
18.9 KB |
|
| |
- REMOXYStill On-Track for June 23 PDUFA Date -
- Cash Position Increased to $98.5 Million -
- No Change to Financial Guidance for 2011 -
SAN MATEO, Calif., April 27, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the first quarter of 2011, which ended March 31, 2011.
Quarterly fi...
|
 |
REMOXY Meets Primary Endpoints in Abuse Liability Study
Apr 25, 2011
|
13.2 KB |
|
| |
REMOXY vs. Oxycodone ER Tested in Volunteers with History of Opioid Abuse -
- Drug Liking Significantly Lower for REMOXY (p...
|
 |
Pain Therapeutics to Present at Needham Health Care Conference
Mar 30, 2011
|
8.3 KB |
|
| |
SAN MATEO, Calif., March 30, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that Peter S. Roddy, Vice President and Chief Financial Officer, will present at the 10th Annual Needham Health Care Conference in New York City on Wednesday, April 6th at 4:00 p.m. Eastern Time.
A live audio webcast of the presentation...
|
 |
Pain Therapeutics to Present at Cowen and Company Health Care Conference
Mar 1, 2011
|
8.2 KB |
|
| |
SAN MATEO, Calif., March 1, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at the Cowen and Company Health Care Conference in Boston on Monday, March 7th at 4:00 p.m. Eastern Time.
A live audio webcast of the presentation will be available on the company's website homepage at www.pa...
|
 |
Pain Therapeutics to Present at RBC Capital Markets Healthcare Conference
Feb 23, 2011
|
8.2 KB |
|
| |
SAN MATEO, Calif., Feb. 23, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at the RBC Capital Markets Healthcare Conference in New York City on Wednesday, March 2nd at 11:00 a.m. Eastern Time.
A live audio webcast of the presentation will be available on the company's website homepa...
|
 |
Pain Therapeutics Announces 2010 Financial Results and Outlines Business Goals for 2011
Feb 3, 2011
|
23.3 KB |
|
| |
REMOXY NDA: PDUFA Date in JuneLIKEABILITY STUDY RESULTS: APS Meeting in MayMELANOMA SURVIVAL DATA: ASCO Meeting in June$91 Million in Cash, No Debt, Cash Requirements in 2011 under $5 Million
SAN MATEO, Calif., Feb. 3, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today reported financial results f...
|
 |
Pain Therapeutics Receives $5,000,000 Payment
Jan 28, 2011
|
9.4 KB |
|
| |
SAN MATEO, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that it had received a $5,000,000 milestone payment from King Pharmaceuticals, Inc. (NYSE:KG), its exclusive commercial partner for abuse-resistant prescription pain medications.
Payment was made in connection with the acceptance by the U....
|
 |
REMOXY New Drug Application Accepted by FDA
Jan 27, 2011
|
9.4 KB |
|
| |
SAN MATEO, Calif., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY® (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
With the Class 2 designation, the FDA has s...
|
 |
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY(R)
Dec 27, 2010
|
11.8 KB |
|
| |
BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 (GLOBE NEWSWIRE) -- King Pharmaceuticals®, Inc. (NYSE:KG) and Pain Therapeutics®, Inc. (Nasdaq:PTIE) today announced that King has resubmitted a New Drug Application (NDA) for REMOXY® (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by P...
|
 |
Pain Therapeutics Completes Special Distribution to Shareholders
Dec 13, 2010
|
7.9 KB |
|
| |
SAN MATEO, Calif., Dec. 13, 2010 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the completion of a special, one-time nondividend cash distribution of $2.00 per share, or an aggregate of about $86 million. In connection with this event, Nasdaq® will adjust the price of PTIE by $2.00 per share at today's open.
"This ma...
|
 |
Pain Therapeutics Awarded $2,000,000 Research Grant
Nov 2, 2010
|
9.7 KB |
|
| |
SAN MATEO, Calif., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive ...
|
|
|
 = add release to Briefcase
|
   |
|
|
|
 |
|